Bolt Biotherapeutics, Inc.
BOLT · Nasdaq · SIC 2834: Pharmaceutical Preparations
Business Summary
3 Item 1A. Risk Factors 19 Item 1B. Unresolved Staff Comments 63 Item 1C. Cybersecurity 63 Item 2. Properties 65 Item 3. Legal Proceedings 65 Item 4. Mine Safety Disclosures 65 PART II Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 66 Item 6. Reserved 66 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations 67 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 78 Item 8. C...
Next Earnings
Q2 FY2026 — expected 2026-08-08
Key Facts from Earnings Calls
| Type | Subject | Detail | Quarter |
|---|
| topic_mention | BOLT | discussed_in_filing Cybersecurity | |
| topic_mention | BOLT | discussed_in_filing Cybersecurity | |
| topic_mention | BOLT | discussed_in_filing Cybersecurity | |
| topic_mention | BOLT | discussed_in_filing Cybersecurity | |
Annual Reports (10-K)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104121 | EDGAR | 81K words |
| 2025-03-24 | 2024-12-31 | 0000950170-25-043873 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034692 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010613 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0000950170-22-005047 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001193125-21-102253 | EDGAR | — |
Quarterly Reports (10-Q)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277549 | EDGAR | 25K words |
| 2025-08-14 | 2025-06-30 | 0001641281-25-000007 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069188 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125413 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096200 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059564 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062048 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0000950170-23-039061 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021233 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024487 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016460 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009664 | EDGAR | — |
Recent Current Reports (8-K)
| Filed | Accession | Source | Full Text |
|---|
| 2026-03-12 | 0001193125-26-104102 | EDGAR | 3K words |
| 2025-11-12 | 0001193125-25-277521 | EDGAR | — |
| 2025-10-02 | 0001193125-25-228293 | EDGAR | — |
| 2025-08-14 | 0001641281-25-000006 | EDGAR | — |
| 2025-06-06 | 0000950170-25-083180 | EDGAR | — |
| 2025-06-04 | 0000950170-25-081607 | EDGAR | — |
| 2025-05-28 | 0000950170-25-077880 | EDGAR | — |
| 2025-05-12 | 0000950170-25-069153 | EDGAR | — |
| 2025-04-16 | 0000950170-25-054871 | EDGAR | — |
| 2025-03-24 | 0000950170-25-043869 | EDGAR | — |
72 total filings indexed. 44 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers
Company Identity
| CIK | 0001641281 |
| Ticker | BOLT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: b357188183f5dc31927f362e78732e2e959910a231942953280fd23b8c171183
parent: 99b89920231f7dcc2c6080347a0dd3af2b108a53576aa74a92b0e9877af0a512
content hash: f5574006c30656188f73c9cd94c6e256123b81f7cb2295d392a1c23abf7403a2
signed: 2026-04-13T04:44:03.604Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf